Revised Statement of Deviation/ Variation

.~. NEOGEN~ ~~ CHEMICALS LTD. July 24, 2026 BSE Limited National Stock Exchange of India Limited Department of Corporate Services Listing Department, Exchange Plaza, Floor 25, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai 400 001 Mumbai – 400 051 Scrip Code No: 542665 Company Symbol: NEOGEN Debt Segment Code: 977028 Sub: Statement of deviation or variation in utilisation of funds raised through Preferential Issue for the quarter ended June 30, 2026 and Monitoring Agency Report issued by CRISIL Ratings Limited under regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 (“Listing Regulations”) Dear Sir/Madam, Pursuant to Regulation 32 of Listing Regulations, we enclose herewith Statement of Deviation / Variation (“Statement”) regarding the utilization of funds raised through Preferential Issue for the quarter ended June 30, 2026. The Statement has been duly reviewed by the Audit Committee at its meeting held on July 24, 2026. We are also enclosing the Monitoring Agency Report issued by CRISIL Ratings Limited, appointed to monitor the utilization of the proceeds. Furthermore, we hereby confirm that there has been no deviation or variation in the utilization of proceeds of funds raised through issue of Equity Shares on preferential basis. This intimation is also being uploaded on the Company’s website at https://neogenchem.com/financial-performance/ and https://neogenchem.com/announcements/ under issued of securities tab and at the website of the National Stock Exchange of India Limited (www.nseindia.com) and BSE Limited (www.bseindia.com) . Kindly take the above on your record and disseminate the same for the information of investors. Thanking you, For Neogen Chemicals Limited Unnati Kanani Company Secretary & Compliance Officer Mem. No: A35131 Encl: A/a Registered Office: 1002, Dev Corpora, Cadbury Junction, E: sales@neogenchem.com T: +91 22 2549 7300 Eastern Express Highway, Thane (W) 400 601, India. W: www.neogenchem.com F: +91 22 2549 7399 CIN No. L24200MH1989PLC050919 NEOGEN® •• ., .. CHEMICALS LTD. Quarterly Reporting for Preferential Issue of Equity Shares under Regulation 32 of Listing Regulation. Statement of Deviation L Variation in utilisation of funds raised Name of listed entity Neogen ChemicalsL imited SCRIP Code 542665 NSE Symbol NEOGEN MSEI Symbol NOTLISTED ISIN INE136S01016 No. of times funds raised 1 Mode of Fund Raising Preferential Issue of Equity Shares Date of Raising Funds 18-04-2026 Amount Raised (Rs. In crores) 161 Report filed for Quarter ended 30-06-2026 Monitoring Agency Applicable Monitoring Agency Name, if applicable CRISIL Ratings Limited Is there a Deviation I Variation in use of funds raised NO If yes, whether the same is pursuant to change in terms of a contract or Not Applicable objects, which was approved by the shareholders If Yes, Date of shareholder Approval Not Applicable Explanation for the Deviation I Variation Not Applicable Comments of the Audit Committee after review No comments Comments of the auditors, if any No comments Objects for which funds have been raised and where there has been a See table below deviation, in the following table (Amount in Crores) Original Object Modified Original Modified Funds Amount of Remarks if any Object, if Allocation allocation, if Utilised Deviation/Variation for any any the quarter according to applicable object 1. Investment in wholly owned subsidiaries of the NO 100 Not 100 O Nil Company viz. Neogen Ionics Limited Applicable 2. Meeting Working capital requirements NO 21 21 O Nil 3. General Corporate Purposes" NO 40 40 O Nil 161 161 O Nil "The amount utilized for general corporate purpose does not exceed 25% of the Gross Proceeds. Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the Jund raising document i.e. prospectus, letter of offer, etc c;>_., ci, ~ \SI I Name of Signatory Gopikrishnan Sarathy 'o , ........ J~ I Designation Chief Financial Officer ~~ ~ --. /·°"/, Date 24-07-2026 ~" Registered Office : 1002, Dev Corpora, Opp.Cadbury Junction. E : sales@neogenchem.com T : +91 22 2549 7300 Khopat, Eastern Express Highway, Thane (W) 400 601, India W : www.neogenchem.com F : +91 22 2549 7399 CIN No. L24200MH1989PLC050919 Crisil Ratings Monitoring Agency Report Neogen Chemicals Limited for the quarter ended June 30, 2026 Crisil Ratings Limited 1 Corporate Identity Number: U67100MH2019PLC326247 Registered Office: Lightbridge IT Park, Saki Vihar Road, Andheri East, Mumbai- 400 072. India Phone: +9 1 22 6137 3000 I www.crisilratings.com a company of S&P Global Crisil Ratings CRL/MAR/ NECL/2026-27/1800 July 24, 2026 Neogen Chemicals Limited 1002, Dev Corpora Building, 10th Floor, Opp. Cadbury Junction, Off Pokhran Road No 2, Khopat Thane, Maharashtra - 400601 Dear Sir, Sub: Final Monitoring Agency Report for the quarter ended June 30, 2026 – in relation to the Preferential Issue of Neogen Chemicals Limited (“the Company”) Pursuant to Regulation 162A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ICDR Regulations”) and Monitoring Agency Agreement dated March 06, 2026, entered with the Company, we enclose the Final Monitoring Agency Report, issued by Crisil Ratings Limited, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of Preferential Issue for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Crisil Ratings Limited 2 Corporate Identity Number: U67100MH2019PLC326247 Registered Office: Lightbridge IT Park, Saki Vihar Road,A ndheri East, Mumbai- 400 072. India Phone: +9 1 22 6137 3000 I www.crisilratings.com a company of S&P Global Crisil Ratings Report of the Monitoring Agency (MA) Name of the issuer: Neogen Chemicals Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Not applicable (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Dire [Showing first 8,000 characters — download PDF for full document]